REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

June 14, 2028

Conditions
Asthma
Interventions
DRUG

Mepolizumab

Mepolizumab will be prescribed based on physician decision.

OTHER

Spirometry

Lung function via spirometry will be collected.

Trial Locations (65)

161

GSK Investigational Site, Roma

4000

GSK Investigational Site, Liège

8500

GSK Investigational Site, Kortrijk

9337

GSK Investigational Site, Hohenstein-Ernsttal

12308

GSK Investigational Site, Schenectady

14607

GSK Investigational Site, Rochester

16132

GSK Investigational Site, Genova

17005

GSK Investigational Site, Girona

19140

GSK Investigational Site, Philadelphia

19141

GSK Investigational Site, Philadelphia

20089

GSK Investigational Site, Rozzano

20769

GSK Investigational Site, Glenn Dale

21204

GSK Investigational Site, Towson

29200

GSK Investigational Site, Brest

29379

GSK Investigational Site, Union

30103

GSK Investigational Site, Adairsville

31059

GSK Investigational Site, Toulouse

31904

GSK Investigational Site, Columbus

32209

GSK Investigational Site, Jacksonville

33032

GSK Investigational Site, Homestead

33125

GSK Investigational Site, Miami

33317

GSK Investigational Site, Plantation

34452

GSK Investigational Site, New Orleans

37126

GSK Investigational Site, Verona

40509

GSK Investigational Site, Lexington

42301

GSK Investigational Site, Owensboro

46015

GSK Investigational Site, Valencia

48103

GSK Investigational Site, Ann Arbor

52074

GSK Investigational Site, Aachen

53119

GSK Investigational Site, Bonn

53123

GSK Investigational Site, Schleswig

55905

GSK Investigational Site, Rochester

59000

GSK Investigational Site, Lille

60389

GSK Investigational Site, Frankfurt

64283

GSK Investigational Site, Darmstadt

67091

GSK Investigational Site, Strasbourg

69004

GSK Investigational Site, Lyon

71105

GSK Investigational Site, Aurora

75069

GSK Investigational Site, McKinney

77429

GSK Investigational Site, Cypress

78028

GSK Investigational Site, Kerrville

80131

GSK Investigational Site, Napoli

80923

GSK Investigational Site, Colorado Springs

89052

GSK Investigational Site, Henderson

92037

GSK Investigational Site, La Jolla

92663

GSK Investigational Site, Newport Beach

131044

GSK Investigational Site, Pieve Di Soligo TV

06510

GSK Investigational Site, New Haven

08221

GSK Investigational Site, Linwood

T3B0M3

GSK Investigational Site, Calgary

Unknown

GSK Investigational Site, Calgary

R3L 1Z5

GSK Investigational Site, Winnipeg

M5G 1E2

GSK Investigational Site, Toronto

06614

GSK Investigational Site, Cannes

09042

GSK Investigational Site, Monserrato CA

00128

GSK Investigational Site, Roma

509-6134

GSK Investigational Site, Gifu

760-0018

GSK Investigational Site, Kagawa

105-0003

GSK Investigational Site, Tokyo

142-8666

GSK Investigational Site, Tokyo

173-8606

GSK Investigational Site, Tokyo

90-153

GSK Investigational Site, ?Od?

80-214

GSK Investigational Site, Gdansk

92-213

GSK Investigational Site, Lodz

08025

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY